Based on the key indicators related to Indaptus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Indaptus Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, Indaptus Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 01/19/2025, Non Currrent Assets Other is likely to grow to about 843.3 K, while Net Debt is likely to drop (12.5 M). Key indicators impacting Indaptus Therapeutics' financial strength include:
The financial analysis of Indaptus Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Indaptus Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(18.62 Million)
Indaptus
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Common Stock
Property Plant Equipment
Capital Lease Obligations
Net Invested Capital
Property Plant And Equipment Gross
Capital Stock
Net Working Capital
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Indaptus Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Indaptus Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Indaptus Therapeutics' assets may result in an increase in income on the income statement.
Indaptus Therapeutics competes with Rezolute, Tempest Therapeutics, Forte Biosciences, ABVC Biopharma, and Pasithea Therapeutics. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Indaptus Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Indaptus Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Indaptus Therapeutics's current stock value. Our valuation model uses many indicators to compare Indaptus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Indaptus Therapeutics competition to find correlations between indicators driving Indaptus Therapeutics's intrinsic value. More Info.
Indaptus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Indaptus Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Indaptus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Indaptus Therapeutics Systematic Risk
Indaptus Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Indaptus Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Indaptus Therapeutics correlated with the market. If Beta is less than 0 Indaptus Therapeutics generally moves in the opposite direction as compared to the market. If Indaptus Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Indaptus Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Indaptus Therapeutics is generally in the same direction as the market. If Beta > 1 Indaptus Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Indaptus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Indaptus Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Indaptus Therapeutics growth as a starting point in their analysis.
Indaptus Therapeutics January 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Indaptus Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Indaptus Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Indaptus Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Indaptus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Indaptus Therapeutics's daily price indicators and compare them against related drivers.
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.